Coherus Oncology, Inc. (CHRS)
0.99
-0.08
(-7.48%)
USD |
NASDAQ |
Oct 16, 16:00
1.01
+0.02
(+2.02%)
After-Hours: 20:00
Coherus Oncology Research and Development Expense (Annual) : 104.96M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 104.96M |
| December 31, 2024 | 86.56M |
| December 31, 2023 | 102.04M |
| December 31, 2022 | 195.66M |
| December 31, 2021 | 359.65M |
| December 31, 2020 | 139.87M |
| December 31, 2019 | 90.82M |
| Date | Value |
|---|---|
| December 31, 2018 | 106.38M |
| December 31, 2017 | 160.53M |
| December 31, 2016 | 254.44M |
| December 31, 2015 | 212.68M |
| December 31, 2014 | 78.22M |
| December 31, 2013 | 31.28M |
| December 31, 2012 | 34.89M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Enanta Pharmaceuticals, Inc. | 106.74M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |